SCHEMBL6090265

SCHEMBL6090265

O=C1NC(c2ccc(OCCO)cc2)N2CCC(=NO)c3cccc1c32

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR174 Q9BXC1 1/20 0.36
ESR1 P03372 4/20 0.34
ESR2 Q92731 1/20 0.34
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PARP1 P09874 1/20 0.32
TNKS2 Q9H2K2 1/20 0.31
KEAP1 Q14145 1/20 0.31
BRAF P15056 2/20 0.30
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30
PKM P14618 1/20 0.30
PDCD1 Q15116 1/20 0.30
CD274 Q9NZQ7 1/20 0.30
HTR3E A5X5Y0 1/20 0.30
HTR3B O95264 1/20 0.30
HTR3A P46098 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6093054 0.88 GPR174 (0.41) GPR174ESR1ESR2GAAKDM4E
SCHEMBL6089391 0.83 ALDH1A1 (0.42) GAAKDM4EUSP2ALDH1A1HSD17B10
SCHEMBL6089398 0.83 ALDH1A1 (0.42) GAAKDM4EUSP2ALDH1A1HSD17B10
SCHEMBL6090599 0.83 TNKS2 (0.35) GAAKDM4EALDH1A1PARP1TNKS2
SCHEMBL6090604 0.83 TNKS2 (0.35) GAAKDM4EALDH1A1PARP1TNKS2
SCHEMBL6090262 0.82 HTR2C (0.31) KDM4EALDH1A1TNKS2
SCHEMBL6090498 0.82 TNKS2 (0.38) GAAKDM4EUSP2ALDH1A1HSD17B10
SCHEMBL6091167 0.82 PARP1 (0.42) ESR1ESR2GAAKDM4EALDH1A1
SCHEMBL6090492 0.82 TNKS2 (0.38) GAAKDM4EUSP2ALDH1A1HSD17B10
SCHEMBL6092454 0.82 MEN1 (0.38) GAAKDM4EALDH1A1PARP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 GPR174 3747/4885ESR1 2745/4885ESR2 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.